A New Prescription Nasal Spray Providing Hope to Dementia Patients and their Carers

Presenting at Sachs 3rd Neurosciences Innovation Forum Sunday, January 12, 2020 at 12:05 PM Marines' Memorial Club in San Francisco, California

Presenting at Biotech Showcase Tuesday January 14, 2020 9:30 AM Hilton San Francisco Union Square in San Francisco, California.

Key Takeaways

Targeting Alzheimer’s Disease with a Proven Mechanism of Action.
2 assigned patents for LBIO-R32 Offering Improved Tolerability vs. Existing Formulation of Rivastigmine.
Expedited Path to Market with a significantly De-risked Asset.

SAN FRANCISCO, Jan. 9, 2020 – LACHESIS BIOSCIENCES LTD, a clinical-stage biotechnology company targeting dementia caused by Alzheimer’s and Parkinson’s disease, announced today that its chief executive officer, Dr. Tim Morgan, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.

General presentation information: Lachesis is developing a patented rivastigmine nasal spray candidate that’s low-risk, with high-return potential. Our presentation includes positive clinical and usability data, future-plans and emphasizes why you should trust us to advance dementia treatment. We make it easier for patients to take higher doses of this important dementia medication.

About LACHESIS BIOSCIENCES

A clinical-stage biotechnology company using its patented, nasal drug delivery technology to advance treatments for dementia and agitation associated with Alzheimer’s and Parkinson’s disease.

Key Takeaways

Targeting Alzheimer’s Disease with a Proven Mechanism of Action.
2 assigned patents for LBIO-R32 Offering Improved Tolerability vs. Existing Formulation of Rivastigmine.
Expedited Path to Market with a significantly De-risked Asset.

Media Gallery

Files

Lachesis Standard News.pdf

Federal government grant for world-first dementia treatment invented in Warrnambool

Download

Related Bios

Dr Timothy Morgan

Chief Executive Officer and Managing Director, Founder

im is a founder of the Company and has been a Director since 2005. He was a founder and Director of Business Development at Acrux Limited. He has more than 18 years of experience in the pharmaceutical industry. He commenced his career at Glaxo in 1992 then undertook his higher degree research training at Monash University from 1994 to 1998 before founding Acrux Limited in 1999 and Lachesis Biosciences in August 2005. He has a Bachelor of Pharmacy with Honours and PhD from Monash University. He is a registered Pharmacist in Australia. His PhD research was competitively recognised both locally and internationally. To date, three prescription pharmaceutical products for which he was named as co-inventor have received marketing approval.

View Full Bio>>

Mr Christian Nicks

Non-Executive Chairman

Christian was appointed as a Director and Chairman in July 2016. He is an investment banker with over 18 years of experience working in Australia, the United States, Japan, Hong Kong and the United Kingdom. He has advised on some of the largest transactions in the healthcare sector in Australia. He spent over 10 years at Goldman Sachs working in the healthcare, telecoms, industrials, financial sponsors and mining sectors. In 2010, he left Goldman Sachs to become Head of Investment Banking at Investec Australia and led a team of professionals to substantially grow Investec’s advisory business. He left Investec in 2014 to establish Valkyrie Corporate Advisory Partners, which provides specialised investment banking and corporate advisory services. He graduated from Stanford University with a Bachelor of Arts in Economics. He is a Member of the Australian Institute of Company Directors.

View Full Bio>>

Dr Amanda Reese

Non-Executive Director

Amanda was appointed as a Director in July 2016. She is a commercial strategy and licensing specialist with over 18 years of experience in the pharmaceutical industry locally and overseas. She spent over 12 years at CSL from 2002 to 2015, most recently as Associate Director for In-Licensing. At CSL she gained broad experience across business development, regulatory affairs, medical affairs, R&D commercialisation, brand management and in-licensing roles. Her extensive commercial expertise is applied to her current executive role as Director Commercialisation and Business Development at Peter MacCallum Cancer Centre whom she joined in May 2019 after 4 years at Paranta Biosciences in a similar role. She commenced her career in specialty pharmaceuticals at AstaMedica in 1997. She has experience in a growth-stage, entrepreneurial company whilst at Optiscan Pty Ltd from 1998 to 2002. She has a Bachelor of Science with Honours and PhD from Monash University.

View Full Bio>>

Contacts

Tim Morgan

tim.morgan@lachesisbio.com.au

+61 418 138 877

Chief Executive Officer